Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types. It has a longer half-life compared to other benzodiazepines, allowing for less frequent dosing.
## Primary Indications
Adjunctive therapy for seizures in patients with Lennox-Gastaut syndrome (LGS). May be used for other seizure types based on clinical judgment and local protocols.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Initiation: 5 mg twice daily.
* Titration: Increase dose every 3 days as needed and tolerated, up to a maximum of 20 mg twice daily.
* Maintenance: Doses can be adjusted based on efficacy and tolerability.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) - Ages 2 years and older:**
* **2 to 10 years:**
* Initiation: 5 mg once daily.
* Titration: Increase dose every 3 days as needed and tolerated, up to a maximum of 10 mg twice daily.
* **Over 10 years:**
* Initiation: 5 mg twice daily.
* Titration: Increase dose every 3 days as needed and tolerated, up to a maximum of 20 mg twice daily.
* **Children under 2 years:** Dosing is not well-established; use with caution and at the lowest effective dose.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary. Specific guidelines are not well-defined.
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised, especially in severe impairment.
* **Concomitant Medications:** Clobazam is metabolized by CYP2C19. Inhibitors of CYP2C19 (e.g., fluconazole, omeprazole) can increase clobazam levels. Inducers of CYP2C19 can decrease levels.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
**Common:** Drowsiness, somnolence, lethargy, irritability, aggression, constipation, ataxia, dizziness, fatigue, drooling, respiratory depression.
**Serious:** Suicidal ideation/behavior, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), dependence and withdrawal symptoms, paradoxical reactions (increased seizure frequency or severity), respiratory depression.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depression, increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole, fluvoxamine, omeprazole):** Increased clobazam plasma concentrations, potentially leading to enhanced adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** Decreased clobazam plasma concentrations.
* **Other Antiepileptic Drugs (AEDs):** Potential for additive CNS depression. Some AEDs can induce or inhibit CYP2C19, affecting clobazam levels.
## Monitoring
* Assess for seizure frequency and severity.
* Monitor for adverse effects, particularly sedation, dizziness, respiratory changes, and behavioral changes.
* Monitor for signs of dependence and withdrawal if discontinuing.
* Consider therapeutic drug monitoring if efficacy or toxicity is a concern, especially with interacting medications.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Due to its long half-life, it can be dosed once or twice daily.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering is recommended.
* Behavioral and psychiatric adverse events, including suicidal ideation, have been reported. Patients and caregivers should be advised to report any such changes.
* The active metabolite, N-desmethylclobazam, contributes significantly to the drug's anticonvulsant activity and has a longer half-life than clobazam itself.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines for complete details before making any treatment decisions.
